Carcinoma in situ and dysplasia of the gallbladder: the decisions you may face

This setting names no product or technology record yet; the approach above is the standard as written. Ask your team which specific treatments they mean.

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

No side-effect rates or interaction flags are recorded for these options yet. The side-effect lookup and interaction checker cover the products that have them.

1. Which specific treatments are you proposing for this setting, and what are the alternatives?
   Why: The standard of care here is described in words rather than named products; ask for the names.
2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
   Why: The aim shapes how much side effect and disruption is worth accepting.
3. What happens if I delay, or decline this step for now? Is the decision reversible?
   Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
4. For my situation (tis or dysplasia with a clear cystic duct margin), which of the standard options do you recommend and why?
   Why: Guideline options include: No further surgery; follow-up because occasional late recurrences reflect a field effect.

Add these to your appointment list, or take the full question set for this cancer.

This setting names no product or technology record yet; the approach above is the standard as written. Ask your team which specific treatments they mean.

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

No side-effect rates or interaction flags are recorded for these options yet. The side-effect lookup and interaction checker cover the products that have them.

1. Which specific treatments are you proposing for this setting, and what are the alternatives?
   Why: The standard of care here is described in words rather than named products; ask for the names.
2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
   Why: The aim shapes how much side effect and disruption is worth accepting.
3. What happens if I delay, or decline this step for now? Is the decision reversible?
   Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
4. For my situation (positive cystic duct margin or rokitansky-aschoff sinus involvement), which of the standard options do you recommend and why?
   Why: Guideline options include: Consider bile duct margin re-excision or further surgery at a hepatobiliary centre.

Add these to your appointment list, or take the full question set for this cancer.

This setting names no product or technology record yet; the approach above is the standard as written. Ask your team which specific treatments they mean.

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

No side-effect rates or interaction flags are recorded for these options yet. The side-effect lookup and interaction checker cover the products that have them.

1. Which specific treatments are you proposing for this setting, and what are the alternatives?
   Why: The standard of care here is described in words rather than named products; ask for the names.
2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
   Why: The aim shapes how much side effect and disruption is worth accepting.
3. What happens if I delay, or decline this step for now? Is the decision reversible?
   Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
4. For my situation (gallbladder polyp in primary sclerosing cholangitis), which of the standard options do you recommend and why?
   Why: Guideline options include: Cholecystectomy advised for polyps of any size by international guidelines; a 2020 cohort supports short-interval imaging first when no high-risk feature is present.

Add these to your appointment list, or take the full question set for this cancer.